This evidence suggests a prospective therapeutic target for the treatment of IBD by inhibiting CHI3L1 expression in the attempt to exclude the entry route of invasive species from the aftermath of intestinal dysbiosis. This evidence concerns the gene CHI3L1 and inflammatory bowel disease.